SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : biotech firesales
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: Julius Wong4/26/2016 7:56:18 AM
   of 3661
 
Sarepta off 54% premarket
  • Fresh off a negative Ad Comm vote, Sarepta Therapeutics (NASDAQ: SRPT) is down 54% premarket on robust volume.
  • From Oppenheimer: "Panel givers FDA an out; unless they apply unprecedented flexibility: Dr. Jane Woodcock's remarks emphasized patients paying the prices for type 2 errors (not approving drugs that work), and that AdCom tracked in lin with our expectations. Broader FDA involvement in the review was clear, could provide an opportunity to do the unprecedented, though we caution unlikely."
  • Previously: Ad Comm thumbs down on eteplirsen; expect volatility tomorrow (April 25)
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News